| Joyce J Abraham, MD | |
|
2206 Club Creek Cir, Garland, TX 75043-1479 | |
| (214) 598-7927 | |
| Not Available |
| Full Name | Joyce J Abraham |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 21 Years |
| Location | 2206 Club Creek Cir, Garland, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568598183 | NPI | - | NPPES |
| 187628601 | Medicaid | TX | |
| 8AH310 | Other | TX | BCBS PROVIDER NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | M5997 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical City Dallas Hospital | Dallas, TX | Hospital |
| Entity Name | Texas Anesthesia Partners, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144673468 PECOS PAC ID: 3870879828 Enrollment ID: O20170406000406 |
News Archive
"The AIDS Institute thanks Chairman Tom Harkin for his leadership in maintaining the United States Senate's strong commitment to domestic HIV programs by increasing funding for the AIDS Drug Assistance Program (ADAP) and maintaining funding for HIV prevention and other parts of the Ryan White HIV/AIDS Program," commented Carl Schmid, Deputy Executive Director of The AIDS Institute.
A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.
› Verified 2 days ago
| Entity Name | Zenith Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497282594 PECOS PAC ID: 9335418714 Enrollment ID: O20170628000019 |
News Archive
"The AIDS Institute thanks Chairman Tom Harkin for his leadership in maintaining the United States Senate's strong commitment to domestic HIV programs by increasing funding for the AIDS Drug Assistance Program (ADAP) and maintaining funding for HIV prevention and other parts of the Ryan White HIV/AIDS Program," commented Carl Schmid, Deputy Executive Director of The AIDS Institute.
A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.
› Verified 2 days ago
| Entity Name | Lighthouse Anesthesia Pllc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528616042 PECOS PAC ID: 9335470574 Enrollment ID: O20200331001918 |
News Archive
"The AIDS Institute thanks Chairman Tom Harkin for his leadership in maintaining the United States Senate's strong commitment to domestic HIV programs by increasing funding for the AIDS Drug Assistance Program (ADAP) and maintaining funding for HIV prevention and other parts of the Ryan White HIV/AIDS Program," commented Carl Schmid, Deputy Executive Director of The AIDS Institute.
A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.
› Verified 2 days ago
| Entity Name | Hill Regional Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679189856 PECOS PAC ID: 6002220464 Enrollment ID: O20210126000758 |
News Archive
"The AIDS Institute thanks Chairman Tom Harkin for his leadership in maintaining the United States Senate's strong commitment to domestic HIV programs by increasing funding for the AIDS Drug Assistance Program (ADAP) and maintaining funding for HIV prevention and other parts of the Ryan White HIV/AIDS Program," commented Carl Schmid, Deputy Executive Director of The AIDS Institute.
A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.
› Verified 2 days ago
| Entity Name | Abraham Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356121107 PECOS PAC ID: 7810348992 Enrollment ID: O20240112003537 |
News Archive
"The AIDS Institute thanks Chairman Tom Harkin for his leadership in maintaining the United States Senate's strong commitment to domestic HIV programs by increasing funding for the AIDS Drug Assistance Program (ADAP) and maintaining funding for HIV prevention and other parts of the Ryan White HIV/AIDS Program," commented Carl Schmid, Deputy Executive Director of The AIDS Institute.
A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joyce J Abraham, MD 2206 Club Creek Cir, Garland, TX 75043-1479 Ph: () - | Joyce J Abraham, MD 2206 Club Creek Cir, Garland, TX 75043-1479 Ph: (214) 598-7927 |
News Archive
"The AIDS Institute thanks Chairman Tom Harkin for his leadership in maintaining the United States Senate's strong commitment to domestic HIV programs by increasing funding for the AIDS Drug Assistance Program (ADAP) and maintaining funding for HIV prevention and other parts of the Ryan White HIV/AIDS Program," commented Carl Schmid, Deputy Executive Director of The AIDS Institute.
A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.
› Verified 2 days ago
Bernard Frank Srubar, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5429 Naaman Forest Blvd, #306, Garland, TX 75044 Phone: 972-414-7171 Fax: 972-414-6620 | |
Dr. Raynaldo Rivera Ortiz Jr., MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 700 Walter Reed Blvd, Suite 305, Garland, TX 75042 Phone: 972-276-6100 | |
Dr. David Lawrence Metz, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 7150 N President George Bush Hwy, Suite 101, Garland, TX 75044 Phone: 214-703-1800 | |
Kenneth R Horak, DO Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 1809 Country Club Cir, Garland, TX 75043 Phone: 972-896-2693 | |
Mrs. Linda Ann Lutz, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 777 Walter Reed, Premier Surgery Center, Garland, TX 75042 Phone: 972-494-0005 |